An AI tool appeared superior to two FDA-approved biomarkers for predicting how people with cancer will respond to immune ...

Northwestern Medicine investigators have developed a new avenue to reprogram compromised immune cells to act against tumors, ...

The DeGregorio Family Foundation with support from the Torrey Coast Foundation Gastro Esophageal Investigator Network ...

Feasibility and safety results from RAD-IO: A multi-stage trial of durvalumab (Medi4736) with chemoradiotherapy with 5-fluorouracil and mitomycin C in patients with muscle-invasive bladder cancer.

Niraparib in patients with BRCA-mutated unresectable or recurrent biliary tract, pancreatic and other gastrointestinal cancers: An investigator-initiated phase 2 trial (NIR-B trial). This is an ASCO ...

A new study shows that neutralising GDF-15 restores immune response in advanced cancers resistant to PD-1 blockade.

Discover a study that describes a host-intrinsic mechanism responsible for the failure of PD-L1 blockade in ovarian cancer.

Despite the established links between inflammation and cancer development, the effects of inflammatory signaling on cancer ...

Compugen's innovative approach targets under-explored immune pathways like PVRIG and IL-18 binding protein. Read why I'm ...

While immune checkpoint blockade therapies, a type of immunotherapy that uses drugs to block specific proteins on immune cells called "checkpoints" from fully attacking cancer cells, have shown ...